Denitsa Stoyanova, a senior distressed credit analyst at 9fin, shares insights into Cerba, a French lab company facing severe financial turmoil. Cerba's debt has soared amidst government tariff cuts, with creditors now organizing for potential negotiations. The unexpected resignation of CEO Emmanuel Ligner adds to the drama, while net leverage ratios climb. Denitsa discusses critical cost-saving strategies, the impact of asset sales, and the urgency for Cerba to reduce its staggering debt from $4.8 billion to $2.7 billion for long-term viability.
